top of page

A Note to Our Readers: Our health blog sometimes features articles from third-party contributors. We share ideas and inspiration to guide your wellness journey—but remember, it’s not medical advice. If you have any health concerns or ongoing conditions, always consult your physician first before starting any new treatment, supplement, or lifestyle change.

CLIA Kit Accuracy: 5 Factors That Affect Chemiluminescent Immunoassay Results

Writer: Monica Pineider
Monica Pineider
57 minutes ago
9 min read

Laboratory methods overview


Chemiluminescent immunoassay (CLIA) kits produce a light signal when assay reagents bind to a target. A reader measures that signal and, when the assay is designed for quantitative measurement, uses its calibration curve to estimate the target concentration.


But asking whether CLIA kits accuracy is “good” cannot be answered for every kit at once. Performance depends on the specific analyte, sample type, assay design, instrument, protocol, and intended use. A kit validated for one matrix or species may not perform the same way in another. The manufacturer’s detection limit is not a guarantee that every sample result is accurate.


Scientist in protective equipment using a pipette in a laboratory.
Consistent sample handling and pipetting are among the practical steps that support reliable immunoassay results; this stock photo is illustrative.

Quick Answer

A CLIA kit can give reliable results when its performance is appropriate for the question and sample, the procedure is followed, and the run passes predefined quality checks. Evaluate accuracy, precision, analytical specificity, and detection capability separately. Sample condition, reagent handling, antibody cross-reactivity, calibrators and controls, and operator or instrument variation are five major sources of error.


Key Takeaways


  • “CLIA” can mean chemiluminescent immunoassay or the U.S. Clinical Laboratory Improvement Amendments. This article uses it for the assay method except in the regulatory clarification below.

  • Accuracy, precision, sensitivity, specificity, and reproducibility are related but distinct performance characteristics.

  • Kit claims apply to stated sample types, species, instruments, and protocol conditions; confirm those details before running samples.

  • Hemolysis, lipemia, interfering antibodies, poor pipetting, unsuitable calibration, and deviations from timing or temperature can affect results, but the effect is assay-specific.

  • Use the kit insert, qualified controls, acceptance criteria, and appropriate verification experiments. A failed run should be investigated—not interpreted by guesswork.

  • Research-use kits are not automatically suitable for diagnosing or making treatment decisions about patients.



Table of Contents




What Does Accuracy Mean for a CLIA Kit?


In measurement science, accuracy describes how close a result is to the true or accepted value. It is not the same as precision, which describes how closely repeated measurements agree. A method can be precise but consistently biased; it can also have a low detection limit without being accurate across the full measuring range.


For an immunoassay, labs may need to consider:


  • Trueness or bias: How close results are to a reference or accepted value.

  • Precision: How much results vary when the same material is measured repeatedly under defined conditions.

  • Analytical specificity: Whether the assay distinguishes the target from related substances or interferents.

  • Detection capability: The lowest amounts the method can detect or quantify with stated confidence.

  • Reportable range and dilution behavior: Whether the assay measures the concentrations expected in the samples.


These characteristics are established for a particular assay and intended use—not for “CLIA kits” as a single category. For example, CLSI’s EP05 addresses precision evaluation, EP07 addresses interference testing, and EP17 addresses detection capability. Their methods and applicability depend on the laboratory question and procedure.


A to Zen’s research guide on LNPEP in oxytocin and vasopressin studies gives an example of why the measurement must match the claim: detecting a protein is different from testing its location or enzymatic activity.



1. Sample Quality and Matrix


An assay can only measure the material that reaches the well. Sample collection, processing, storage, and matrix effects can change the signal or make it harder to interpret.


Potential issues include hemolysis, lipemia, high bilirubin, contamination, degradation, and repeated freeze-thaw cycles. These do not invalidate every assay in the same way: the kit documentation should state known limitations, and the laboratory may need to verify the effect for its own samples. Some analytes may also require a particular anticoagulant, sample dilution, or processing method.


Practical checks:


  • Confirm the kit is validated for the sample type you plan to use (for example, serum, plasma, or culture supernatant) and the species.

  • Follow the kit’s instructions for collection, centrifugation, storage temperature, and allowable freeze-thaw cycles.

  • Record sample appearance and handling history; do not discard or accept a sample solely because it looks cloudy without checking the assay’s criteria.

  • If matrix interference is possible, consider dilution linearity, spike recovery, or comparison with an appropriate method, as justified by the study.


NIST’s procedures for volumetric calibration explain why traceable volume measurements and controlled technique matter in quantitative laboratory work.



2. Reagent Storage and Handling


Reagents may lose activity or behave differently if stored outside the conditions specified by the manufacturer. Light sensitivity, humidity, temperature excursions, contamination, and repeated warming can all matter depending on the component.


There is no universal rule that every reagent should be brought to room temperature or that every kit should be stored at the same temperature. Use the current lot’s instructions. In particular:


  • Check storage conditions and expiration dates for each component.

  • Note any temperature excursions or extended time outside recommended storage.

  • Allow reagents to equilibrate only when and as directed.

  • Mix or reconstitute components exactly as specified; do not combine reagents unless instructed.

  • Keep caps closed and use clean tips to prevent contamination.


For instance, manufacturer protocols for chemiluminescent immunoassays specify reagent preparation and a defined interval between substrate addition and reading. A different kit may require different conditions, so use its own insert rather than transferring timings between products.



3. Antibody Specificity and Cross-Reactivity


Antibodies provide target recognition, but recognition is not always exclusive. A related protein, metabolite, endogenous antibody, or other sample component may bind or interfere and produce a signal that resembles the target. Depending on the assay, interference can increase or decrease the reported result.


Before selecting a kit, review:


  • The target and antibody pair, if disclosed.

  • Cross-reactivity data for structurally related molecules.

  • Species reactivity and the sample types actually evaluated.

  • Known interference from heterophile or anti-animal antibodies, biotin, rheumatoid factor, or other substances relevant to the method.

  • Whether validation was performed by the manufacturer, the lab, or both—and in which matrix.


A datasheet’s claim that a kit “reacts with human samples” does not necessarily establish accuracy for every clinical or research population. If results conflict with expected biology or another method, investigate potential interference rather than assuming the kit or sample is correct. The FDA’s public device review documents, such as this immunoassay interference discussion, illustrate why heterophile antibody effects may be described in product limitations.


For an overview of how researchers distinguish protein abundance, localization, and catalytic activity, see A to Zen’s LNPEP measurement guide.



4. Calibrators, Controls, and the Standard Curve


A calibration curve translates measured signal into an estimated concentration. Poorly prepared standards, an unsuitable curve model, or a curve outside predefined acceptance limits can compromise every sample result on the plate.


Run standards and controls as required by the protocol, and define acceptance criteria before reviewing results. For quantitative assays, controls at more than one concentration can help show whether performance is acceptable across the measuring range. Track control values and lot changes over time; a gradual shift can be easier to spot in a control chart than in a single run.


If a curve or control fails:


  1. Hold the affected results.

  2. Check calculations, dilution steps, reagent preparation, instrument settings, and timing.

  3. Review control trends and any kit or lot changes.

  4. Repeat or investigate according to the laboratory’s written procedure.

  5. Document the decision and do not report values by manually “correcting” a failed curve.


Standards such as CLSI EP05, EP07, and EP17 address different questions—precision, interference, and detection capability. They are not interchangeable and do not, by themselves, certify a kit as accurate for every intended use.


Gloved hands using a pipette with laboratory samples.
Standards and controls help laboratories assess whether a run meets its predefined acceptance criteria.


5. Pipetting, Timing, and Instrument Conditions


Small volume differences can matter, particularly when working near the assay’s lower measurement range. Inconsistent aspiration, incorrect tip fit, bubbles, incomplete washing, plate-edge effects, uneven incubation, and a delay in reading can add variation.


A practical run checklist:


  • Use calibrated pipettes within their appropriate volume range and consistent technique.

  • Follow the kit’s recommended plate type, wash method, mixing, incubation time, temperature, and read window.

  • Avoid bubbles and inspect wells before reading; remove them only if the protocol permits.

  • Use the specified reader settings and verify instrument maintenance or calibration status.

  • Keep a run record with operator, kit lot, instrument, reagent preparation, sample dilution, and deviations.


National Institute of Standards and Technology (NIST)’s volumetric transfer guidance covers pipette handling and performance expectations. The goal is not merely to “be careful,” but to standardize the steps that can change delivered volume and signal.


Laboratory scientist using a pipette to transfer a sample.
Pipetting technique, timing, and adherence to the specific kit protocol can affect assay variability.


CLIA Assay Chemistry Versus CLIA Regulation


In this article, CLIA generally means chemiluminescent immunoassay. In the United States, CLIA also means the Clinical Laboratory Improvement Amendments, the federal program administered by the Centers for Medicare & Medicaid Services (CMS) for laboratories testing human specimens for health assessment or diagnosis, prevention, or treatment.


The two meanings are separate. A kit using chemiluminescent detection is not automatically “CLIA certified.” CMS certification applies to laboratories and their testing operations. Separately, the FDA assigns complexity categories to specific clinical in vitro diagnostic test systems; a waiver applies to the particular test system and its authorized instructions, not to research kits generally. See the official CMS CLIA program page, CMS test-complexity overview, and FDA CLIA categorizations. CMS notes that applicants must use the revised CMS-116 form starting November 9, 2026.


Research-use-only kits should not be used to diagnose or guide patient treatment unless the product and laboratory process are appropriately authorized and validated for that purpose. A product’s analytical performance claim is not the same as clinical validation or regulatory authorization.



Evidence Snapshot

CLSI guidance treats precision, interference, and detection capability as distinct evaluation questions. CMS CLIA requirements apply to qualifying U.S. laboratories testing human specimens; the acronym does not certify an assay kit. For any specific kit, its current instructions, intended use, sample matrix, and the laboratory’s own verification determine what its results can support.

Expert Tip

Before buying or running a kit, write down the measurand, sample matrix, species, expected concentration range, instrument, and decision the result will inform. Then compare those needs with the kit insert. If even one does not match, ask the supplier for validation data or plan an appropriate verification before relying on the result.

Myth vs Fact


Myth

Fact

“A low detection limit means the kit is accurate.”

Detection capability is only one performance characteristic; it does not establish bias, precision, or specificity.

“A CLIA kit is certified by the U.S. CLIA program.”

CMS CLIA certification applies to eligible laboratories and testing operations, not to kits as a blanket approval.

“A cloudy or hemolyzed sample always has to be discarded.”

Interference depends on the analyte and assay; use the kit’s limits and laboratory acceptance policy.

“A standard curve that looks smooth means the run passed.”

Standards, controls, and predefined acceptance criteria must all be considered.

“Repeating a failed run fixes the problem.”

Repeating without identifying and documenting the cause can reproduce the error.



Four Questions Before the Next Run


  • Is this kit validated for my target, sample type, species, and expected concentration range?

  • Were all samples and reagents handled according to the current kit insert?

  • Did standards and controls meet predefined acceptance criteria?

  • Are the pipette, instrument settings, incubation, wash, and read steps within specification?


If any answer is no or unknown, pause and resolve the issue before interpreting sample results.



Conclusion


CLIA kit accuracy is not a property that can be summarized with one detection limit or a broad claim that the technology is “highly sensitive.” Reliability depends on the exact assay and how it is used. Check sample compatibility, reagent handling, antibody specificity, calibration and controls, and operator or instrument conditions. Then interpret the result only within the kit’s validated range and the laboratory’s intended use.



Frequently Asked Questions


Are CLIA kits accurate?


Some kits can produce reliable results for their validated use when the procedure is followed and quality checks pass. Performance is assay-specific; compare the stated sample type, species, range, precision, interference, and detection data with your own requirements.


What is the difference between accuracy and precision?


Accuracy describes closeness to a true or accepted value. Precision describes agreement among repeated measurements. A method can be precise but biased, so both characteristics matter.


Does high sensitivity mean a CLIA kit is more accurate?


No. Sensitivity or detection capability describes how well low amounts can be detected under stated conditions. It does not by itself show that quantified results are unbiased, reproducible, or specific.


What causes inconsistent CLIA kit results?


Common contributors include sample matrix effects, sample degradation, inconsistent pipetting, reagent storage excursions, cross-reactivity or interference, calibration problems, timing differences, instrument settings, and operator variation.


What does CLIA mean on a kit datasheet?


Usually, in this context, it means chemiluminescent immunoassay. It should not be confused with the U.S. Clinical Laboratory Improvement Amendments program, which regulates qualifying laboratories testing human specimens.


Can research-use-only CLIA kits be used for patient diagnosis?


Not simply because they produce a numerical result. Research-use-only labeling and analytical claims do not establish authorization or validation for clinical diagnosis. Laboratories should follow applicable regulatory requirements and use methods appropriate to the intended clinical purpose.



References


  1. Clinical and Laboratory Standards Institute. EP05 Plus: Evaluation of Precision of Quantitative Measurement Procedures.

  2. Clinical and Laboratory Standards Institute. EP07 Plus: Interference Testing in Clinical Chemistry.

  3. Clinical and Laboratory Standards Institute. EP17: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures.

  4. Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments (CLIA).

  5. Centers for Medicare & Medicaid Services. Apply for a CLIA Certificate.

  6. National Institute of Standards and Technology. Selected Procedures for Volumetric Calibrations.

  7. Thermo Fisher Scientific. Basic Sandwich ELISA Protocols: Chemiluminescent Sandwich ELISA.

  8. U.S. Food and Drug Administration. Immunoassay device review discussing heterophile antibody interference.

  9. U.S. Food and Drug Administration. CLIA Categorizations.


Disclaimer


This article is for general laboratory education and is not a substitute for the kit’s current instructions, a validated laboratory procedure, regulatory advice, or qualified technical support. It does not establish that any particular assay is fit for a specific research or clinical purpose. Follow applicable institutional, regulatory, biosafety, and quality requirements.

Recent Posts

About the Author​

 

Monica Pineider is the author of the A to Zen Therapies health blog and founder of a Central London wellness clinic. She specialises in massage therapy and holistic treatments, drawing on professional experience since 2009 in reflexology, shiatsu, and deep tissue massage.

 

She trained in Thailand and Bali in traditional massage techniques before continuing advanced hands-on study in London across multiple therapy disciplines. This international and clinical background has shaped the approach and philosophy of A to Zen Therapies.

 

Monica oversees the editorial direction of every article published on the blog, including content written or contributed to by external specialists in areas beyond the clinic’s direct clinical experience. All content is reviewed to ensure clarity, accuracy, and alignment with our editorial standards.

 

She shares practical, experience-based insights to support relaxation, recovery, and everyday wellbeing.

​

​

⚠️ Medical Disclaimer

 

The information provided on this website is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment.

 

Always seek the advice of your physician, qualified healthcare provider, or other licensed medical professional regarding any medical condition, symptoms, or treatment options. Do not disregard professional medical advice or delay seeking it because of information you have read on this website.

 

A to Zen Therapies and its contributors provide information for general informational purposes only and may not reflect individual medical circumstances. Individual results from wellness practices, supplements, or natural therapies may vary.

 

If you are pregnant, nursing, taking medication, or have a pre-existing health condition, consult a qualified healthcare professional before starting any new wellness routine, supplement, or therapy.

 

Use of this website and its content is at your own risk.

​

​

Editorial Note

​

This article has been reviewed in accordance with A to Zen Therapies’ Editorial Policy to ensure accuracy, clarity, and responsible, experience-based wellness information.

bottom of page